Clinical Integration Program definition

Clinical Integration Program means the active and ongoing program of clinical quality, efficiency, and cost effectiveness initiatives developed, implemented, and operated by GSQN on behalf of and in collaboration with GSQN Members and GSQN participating physician practices.
View Source
Clinical Integration Program means a formal, non-exclusive, active and ongoing program of clinical quality initiatives developed, implemented, and operated by CIN in collaboration with Provider in order to create a high degree of coordination and interdependence among Participating Providers with the intent to increase value and efficiency, and improve patient outcomes and includes one or more of the following operating protocols:
View Source
Clinical Integration Program or “CI Program” shall mean the program of Clinical Integration developed, implemented, and operated by CIN on behalf of and in collaboration with CIN’s Participants and Participating Practices.
View Source

Examples of Clinical Integration Program in a sentence

  • GSQN is a Louisiana limited liability company organized for the purpose of developing and operating the Clinical Integration Program described herein.

  • Group shall not share rates or any other competitively sensitive information related to the Clinical Integration Program with non- participating groups or physicians.

  • CIN shall receive Shared Savings payments from Payors and, after deducting costs and expenses pursuant to Section 1.6, CIN shall pay Provider the Provider Portion of the Shared Savings and other financial incentive payments under agreements negotiated by CIN as part of the Clinical Integration Program consistent with the CIN Policies and Procedures and as established by the Board of Directors.

  • Group and CI Participating Physicians shall actively participate in the development and implementation of the Clinical Integration Program including, but not limited to, participation on committees upon request of MCHP.

  • Each Participating Physician shall meet Clinical Integration Program training requirements as provided in MCHP written policies and procedures.

  • Group and CI Participating Physicians shall abide by and comply with any quality improvement, safety, disease management and utilization management programs, processes and procedures and the related clinical protocol standards and other requirements of the Clinical Integration Program.

  • Participating Practices and each primary care provider will cooperate with the IPA in the development and implementation of the IPA’s Clinical Integration Program, which is described more fully below and will be supplemented from time to time by policies and procedures adopted by the Board of Directors of the IPA.

  • The State shall provide technical assistance and support and other program components as part of the Community & Clinical Integration Program (CCIP), as detailed in Section 5 (A) (Specification of Services).

  • CIN will negotiate contracts with Payors, which Providers will be given the opportunity to Opt Out of within ten (10) business days of receiving the Network Commencement Notice, related to the Clinical Integration Program and will perform its obligations pursuant to the terms of such Payor contracts.

  • If Group performs below clinical protocol targets or fails to meet any other Clinical Integration Program requirements, Group shall work cooperatively with MCHP in accordance with established MCHP written policies and procedures to develop a corrective action plan to improve performance.

Related to Clinical Integration Program

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Development Program means the implementation of the development plan.